JPH10245391A - ７−グリコシロキシベンゾピラン誘導体を有効成分とする糖尿病治療剤 - Google Patents

７−グリコシロキシベンゾピラン誘導体を有効成分とする糖尿病治療剤

Info

Publication number
JPH10245391A
JPH10245391A JP9047963A JP4796397A JPH10245391A JP H10245391 A JPH10245391 A JP H10245391A JP 9047963 A JP9047963 A JP 9047963A JP 4796397 A JP4796397 A JP 4796397A JP H10245391 A JPH10245391 A JP H10245391A
Authority
JP
Japan
Prior art keywords
compound
benzopyran
group
tetra
acetyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP9047963A
Other languages
English (en)
Japanese (ja)
Other versions
JPH10245391A5 (enExample
Inventor
Hideji Takagaki
秀次 高垣
Shigenori Nakanishi
滋典 中西
Yasuo Aoki
康夫 青木
Nobuyuki Kimura
信之 木村
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DIC Corp
Original Assignee
Dainippon Ink and Chemicals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Ink and Chemicals Co Ltd filed Critical Dainippon Ink and Chemicals Co Ltd
Priority to JP9047963A priority Critical patent/JPH10245391A/ja
Publication of JPH10245391A publication Critical patent/JPH10245391A/ja
Publication of JPH10245391A5 publication Critical patent/JPH10245391A5/ja
Pending legal-status Critical Current

Links

Classifications

    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP9047963A 1997-03-03 1997-03-03 ７−グリコシロキシベンゾピラン誘導体を有効成分とする糖尿病治療剤 Pending JPH10245391A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP9047963A JPH10245391A (ja) 1997-03-03 1997-03-03 ７−グリコシロキシベンゾピラン誘導体を有効成分とする糖尿病治療剤

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP9047963A JPH10245391A (ja) 1997-03-03 1997-03-03 ７−グリコシロキシベンゾピラン誘導体を有効成分とする糖尿病治療剤

Publications (2)

Publication Number Publication Date
JPH10245391A true JPH10245391A (ja) 1998-09-14
JPH10245391A5 JPH10245391A5 (enExample) 2004-12-02

Family

ID=12790005

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9047963A Pending JPH10245391A (ja) 1997-03-03 1997-03-03 ７−グリコシロキシベンゾピラン誘導体を有効成分とする糖尿病治療剤

Country Status (1)

Country Link
JP (1) JPH10245391A (enExample)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6414126B1 (en) 1999-10-12 2002-07-02 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US6555519B2 (en) 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
US6670391B2 (en) 2001-06-28 2003-12-30 Dainippon Ink And Chemicals, Inc. Benzopyran derivative and antiallergic agent
US6683056B2 (en) 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
US6936590B2 (en) 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US7342127B2 (en) 2003-01-24 2008-03-11 Bristol-Myers Squibb Company Substituted anilide ligands for the thyroid receptor
EP2668953A1 (en) 2008-05-22 2013-12-04 Bristol-Myers Squibb Company Pharmaceutical compositions comprising an SGLT2 inhibitor with a supply of carbohydrate and/or an inhibitor of uric acid synthesis
WO2014134703A1 (en) 2013-03-04 2014-09-12 Nova Chemicals (International) S. A. Complex comprising oxidative dehydrogenation unit
CN104861020A (zh) * 2015-06-14 2015-08-26 海南医学院 一个苯丙素苷类化合物、其提取方法及其应用
CN104945455A (zh) * 2014-03-28 2015-09-30 中国医学科学院药物研究所 香豆素苷类化合物、其制法和药物组合物与用途
WO2020016335A1 (en) 2018-07-19 2020-01-23 Astrazeneca Ab Methods of treating hfpef employing dapagliflozin and compositions comprising the same
WO2022022865A1 (en) 2020-07-27 2022-02-03 Astrazeneca Ab Methods of treating chronic kidney disease with dapagliflozin
WO2022208172A1 (en) 2021-04-01 2022-10-06 Astrazeneca Uk Limited Systems and methods for managing prediabetes with a gliflozin sodium-glucose cotransport 2 inhibitor pharmaceutical composition
WO2025125513A1 (en) 2023-12-15 2025-06-19 AstraZeneca Ireland Limited Sglt2 inhibitors and baxdrostat for treating chronic kidney disease and hypertension

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6414126B1 (en) 1999-10-12 2002-07-02 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US6555519B2 (en) 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
US6683056B2 (en) 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
US6936590B2 (en) 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US6670391B2 (en) 2001-06-28 2003-12-30 Dainippon Ink And Chemicals, Inc. Benzopyran derivative and antiallergic agent
US7342127B2 (en) 2003-01-24 2008-03-11 Bristol-Myers Squibb Company Substituted anilide ligands for the thyroid receptor
EP2668953A1 (en) 2008-05-22 2013-12-04 Bristol-Myers Squibb Company Pharmaceutical compositions comprising an SGLT2 inhibitor with a supply of carbohydrate and/or an inhibitor of uric acid synthesis
WO2014134703A1 (en) 2013-03-04 2014-09-12 Nova Chemicals (International) S. A. Complex comprising oxidative dehydrogenation unit
CN104945455A (zh) * 2014-03-28 2015-09-30 中国医学科学院药物研究所 香豆素苷类化合物、其制法和药物组合物与用途
CN104861020A (zh) * 2015-06-14 2015-08-26 海南医学院 一个苯丙素苷类化合物、其提取方法及其应用
WO2020016335A1 (en) 2018-07-19 2020-01-23 Astrazeneca Ab Methods of treating hfpef employing dapagliflozin and compositions comprising the same
WO2022022865A1 (en) 2020-07-27 2022-02-03 Astrazeneca Ab Methods of treating chronic kidney disease with dapagliflozin
WO2022208172A1 (en) 2021-04-01 2022-10-06 Astrazeneca Uk Limited Systems and methods for managing prediabetes with a gliflozin sodium-glucose cotransport 2 inhibitor pharmaceutical composition
WO2025125513A1 (en) 2023-12-15 2025-06-19 AstraZeneca Ireland Limited Sglt2 inhibitors and baxdrostat for treating chronic kidney disease and hypertension

Similar Documents

Publication Publication Date Title
JPH10245391A (ja) ７−グリコシロキシベンゾピラン誘導体を有効成分とする糖尿病治療剤
EP0629602B1 (en) 3,4-Dihydroxychalcone derivatives
KR100350171B1 (ko) 3-또는4-글리코실옥시벤조피란유도체및활성성분으로서이를함유하는알러지치료체
EP0684255B1 (en) 7-Glycosyloxybenzopyran derivative and antiallergic agent containing the derivative as active ingredient
AU726901B2 (en) Benzopyran derivative and use of said benzopyran derivative for treating heart disease
CA1271191A (en) Alpha-tocopherol (halo)uridine phosphoric acid diester, salts thereof, and methods for producing the same
JP3775514B2 (ja) ４−グリコシロキシベンゾピラン誘導体及びそれを有効成分とする抗アレルギー剤
JP3603327B2 (ja) 糖尿病治療剤
JP3775513B2 (ja) ３−グリコシロキシベンゾピラン誘導体及びそれを有効成分とする抗アレルギー剤
JP3716941B2 (ja) 糖尿病治療剤
US6242425B1 (en) Quinolinone glycoside, production process, and anti-allergic agent
US6518250B2 (en) Agent for preventing and curing hindrance of ischemic reperfusion
DE69928382T2 (de) Prophylaxe und heilmittel für mit ischämie-reperfusion zusammenhängenden erkrankungen
EP1488796B1 (en) Chromanol glucosides for ameliorating cancer chemotherapy
EP1163218B1 (en) New salt of (2r,3r,4r)-3,4-dihydroxy-2-hydroxymethylpyrrolidine
JPH08259556A (ja) ４，７−ジヒドロキシベンゾピラン誘導体及びそれを有効成分とする抗アレルギー剤
MXPA02006339A (es) Benzofenonaglicopiranosidos, su preparacion y uso terapeutico.
JPH0892086A (ja) アトピー性皮膚炎治療剤
JP2005179372A (ja) 糖尿病治療剤
JP2002539194A (ja) 新規の（２ｒ，３ｒ，４ｒ）−３，４−ジヒドロキシ−２−ヒドロキシメチルピロリジンの塩
JPH11269191A (ja) キノリノン配糖体、製造方法及び抗アレルギ―剤
JPWO1999039719A1 (ja) 虚血再灌流障害予防および治療剤
KR20030061525A (ko) 1-(4'-알키닐-β-Ｄ-에리트로노퓨라노실)-5-플루오로-Ｎ4-(알킬옥시카르보닐)-사이토신 유도체, 그의 제조방법, 및이를 유효성분으로 포함하는 항암제

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20031212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20031212

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7421

Effective date: 20050621

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070717

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20070719

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20071120